Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan receives NICE recommendation for Ozurdex

Allergan receives NICE recommendation for Ozurdex

6th June 2017

Allergan has announced that its drug Ozurdex has been recommended for routine NHS use following a decision by the National Institute for Health and Care Excellence’s (NICE) .

A final appraisal determination from the UK regulator has endorsed the use of Ozurdex as a cost-effective and efficacious treatment option for people with sight-threatening posterior noninfectious posterior uveitis.

If confirmed as final guidance, it will mean the NHS will be required to offer Ozurdex as a fully funded treatment option for suitable patients who have noninfectious uveitis in the posterior segment of the eye where the disease is active, and there is worsening vision with risk of blindness.

Ozurdex is currently funded for posterior segment uveitis in some parts of the country but not others, meaning its accessibility depends on where the patient lives. Additionally, the process for obtaining funding for Ozurdex is time-consuming and not always successful.

Jessica Hall, advocacy policy project officer from the Royal National Institute of Blind People, said: "Given that the vision loss associated with uveitis is potentially avoidable, it is right that the NHS pays for treatments that NICE has shown are cost and clinically effective in this area."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836562-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.